Skip to main content
Pharma Equity Group A/S logo

Pharma Equity Group A/S — Investor Relations & Filings

Ticker · BLVIS ISIN · DK0061155009 LEI · 2138008SUI4D917FKN20 CO Financial and insurance activities
Open in API
Filings indexed 1,627 across all filing types
Latest filing 2023-03-31 Remuneration Information
Country DK Denmark
Listing CO BLVIS

About Pharma Equity Group A/S

https://bcbsfepvision.com/

Pharma Equity Group A/S is an investment company specializing in early-stage biotechnology, life science, and MedTech companies. The group's mission is to support its portfolio companies in developing novel therapies and effective medicines for unmet medical needs. A primary investment is its subsidiary, Reponex Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious, acute, and chronic inflammatory diseases. The company is actively expanding its portfolio through strategic acquisitions to support its growth.

Recent filings

Filing Released Lang Actions
Remuneration Information 2023
Remuneration Information Classification · 99% confidence The document is explicitly titled "Vederlagsrapport 2022" (Remuneration Report 2022) in Danish. It details compensation for the board of directors and executive management for the fiscal year 2022. Section 7 includes the Board's endorsement, and Section 8 is the independent auditor's declaration regarding the remuneration report, referencing Danish company law (§ 139b). This content directly aligns with the definition of a report detailing compensation for top executives and directors, which corresponds to the 'Remuneration Information' category, coded as DEF 14A in the provided schema, even though the document is Danish and not a US DEF 14A filing, the *content* matches the definition for DEF 14A (Remuneration Information). Since the document is the full report itself and not an announcement of its publication, RPA/RNS is not appropriate. The document length (17296 chars) confirms it is a substantial report, not a brief announcement.
2023-03-31 Danish
Pharma Equity Group A/S - Årsrapport 2022
Annual Report Classification · 100% confidence The document is titled 'Årsrapport 2022' (Annual Report 2022) for Pharma Equity Group A/S. It contains comprehensive financial components including the management statement (Ledelsespåtegning), independent auditor's report (Den uafhængige revisors revisionspåtegning), management review (Ledelsesberetning), and full financial statements (Resultatopgørelse, Balance, Pengestrømsopgørelse, etc.). As it is the complete annual financial report for the fiscal year 2022, it is classified as a 10-K (Annual Report). FY 2022
2023-03-31 Danish
Pharma Equity Group A/S - Årsrapport 2022
Report Publication Announcement Classification · 100% confidence The document is a short announcement (3,702 characters) from Pharma Equity Group A/S regarding the publication of their 2022 Annual Report. It summarizes key financial highlights and provides links to download the actual report and related files. According to the 'Menu vs Meal' rule, since this is a short announcement providing links to the actual report rather than the full report itself, it is classified as a Report Publication Announcement (RPA).
2023-03-31 Danish
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short official announcement (Selskabsmeddelelse) dated March 30, 2023, regarding the total number of voting rights and share capital in Pharma Equity Group A/S, referencing a recent capital increase and Danish capital markets law (§ 32). This type of announcement, which details changes in the total number of shares and voting rights, directly corresponds to a notification about capital structure changes or share issuance. Given the specific content detailing the issuance of new shares following a capital increase, the most appropriate classification is 'Share Issue/Capital Change' (SHA). It is not a general regulatory filing (RNS) because it fits a more specific category, nor is it a proxy statement or dividend notice.
2023-03-30 Danish
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 99% confidence The document is titled "Storaktionærmeddelelse" (Major Shareholder Announcement) and explicitly states that a shareholder's ownership percentage has changed following a capital increase. This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership levels crossing thresholds. The appropriate code is MRQ.
2023-03-30 Danish
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 98% confidence The document is titled "Correction: Storaktionærmeddelelse" (Correction: Major Shareholder Announcement) and explicitly states that a shareholder's ownership stake has changed following a capital increase. This directly relates to changes in significant share ownership levels, which aligns perfectly with the definition for Major Shareholding Notification (MRQ). The document is short and contains specific details about ownership percentage and share count, confirming it is a notification rather than a general regulatory filing or an announcement of a larger report.
2023-03-30 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.